3-28 | by Joanne Liu (the international president of Médecins Sans Frontières.) and Paual Farmer (The co-founder of Partners in Health, Professor of Global Health and Social Medicine at Harvard Medical School, and Chief of the Division of Global Health Equity at Brigham and Women’s Hospital.) Though TB can strike anyone, it disproportionately afflicts marginalized and vulnerable populations in places like refugee camps, slums, and prisons.
3-23 | Despite being curable, the world is losing the battle against tuberculosis (TB). The road ahead is rife with challenges, from diagnosis to treatment, for patients and treatment providers alike. In this Q&A, Dr. Francis Varaine, leader of the MSF working group on Tuberculosis, explains MSF’s priorities over the next ten years. Where are we in the fight against TB? We’re not exactly winning.
3-5 | Turn into this narrow side street from a traffic-choked avenue in Phnom Penh, the capital of Cambodia, and the volume suddenly drops. Removed from the honking tuk-tuks and bathing in shade, a bright mural welcomes visitors to the drop-in centre of a charity, called ‘Mith Samlanh’.
10-31 | Dramatic price drops should allow countries to provide treatment for millions of people On the eve of the World Hepatitis Summit in Sao Paolo, the international medical humanitarian organization Médecins Sans Frontières (MSF) today announced that it had secured deals for generic hepatitis C medicines for as low as US$1.40 per day, or $120 per 12-week treatment course for the two key medicines sofosbuvir and daclatasvir. In the US, pharmaceutical corporation Gilead launched sofosbuvir at $1,000 per pil
10-31 | Dramatic price drops should allow countries to provide treatment for millions of people On the eve of the World Hepatitis Summit in Sao Paolo, the international medical humanitarian organization Médecins Sans Frontières (MSF) today announced that it had secured deals for generic hepatitis C medicines for as low as US$1.40 per day, or $120 per 12-week treatment course for the two key medicines sofosbuvir and daclatasvir. In the US, pharmaceutical corporation Gilead launched sofosbuvir at $1,000 per pil
Pages
eDonation
Field worker
I LIKE MSF
